18F-NaF PET image
November 2, 2009 - PETNET Solutions, a wholly-owned subsidiary of Siemens Medical Solutions, announced it is a registered supplier of 18F-sodium fluoride (18F-NaF) and investigational 3’Deoxy-3’[18F] Fluorothymidine (18F-FLT) to the American College of Radiology Imaging Network (ACRIN) in support of ACRIN’s multi-center clinical trials.
Availability of 18F-NaF and 18F-FLT will be made via a cross reference from Siemens’ Drug Master Files (DMF) to the National Cancer Institutes (NCI) centralized IND’s, under which the ACRIN trial will be performed. The cross reference allows both products to be produced and used by any principle investigator in an ACRIN clinical trial. In addition, the imaging biomarkers will be available to investigators outside of ACRIN trials if they receive independent FDA approval of an IND or appropriate authorization, such as a local Radioactive Drug Research Committee (RDRC) approval or Institutional Review Board (IRB) approval.
18F-FLT has been used in studies to monitor the proliferative activity of cancer cells. 18F-sodium fluoride (18F-NaF) is an FDA-approved imaging agent and will be studied in the detection of bony metastases. Clinical trial support of both imaging agents provides the medical community with better access to 18F-FLT and 18F-NaF by leveraging Siemens biomarker technology and PETNET Solutions as the industry’s largest network of PET biomarker production facilities.
For more information: www.siemens.com/healthcare
October 16, 2026 
